MassBio General Counsel Executive Group Roundtable: Navigating Innovation Partnerships in an Evolving Life Sciences Market

The convergence of life sciences and technology has created tremendous opportunities to accelerate innovation in the industry. This acceleration was further fueled by the COVID-19 pandemic, where the race to develop new therapies and vaccines to treat COVID-19 resulted in an unprecedented number of transactions between and among companies of all shapes and sizes, including competitors. 

This roundtable discussion, led by Matt Karlyn and Mai Zymaris of Morrison & Foerster’s Boston Life Sciences Group, will focus on best practices and considerations for any company entering into a collaboration or licensing deal. Topics include:

• Best practices and pitfalls of negotiating term sheets, including level of detail, exclusivity, binding provisions
• Deal structures, including cost-sharing, co-promotion, options, territory deals, pricing structures, exclusivity, termination provisions/fees, and equity investments
• Additional complexities for new modalities such as ADCs, bi-specifics, and combination therapies
• Increased antitrust scrutiny and considerations for drafting
• Case studies in collaboration, covering lessons learned, and what general counsel need to know in today’s market